Salute e Benessere
GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products
"Adding automated aseptic fill-finish capabilities to our service offerings strengthens our ability to meet the diverse requirements of our clients, from start-up biotech to established pharmaceutical companies," said Karl Pinto , & CEO at GBI. "Our facility is equipped with state-of-the-art technology and a team of experts, capable of delivering high-quality, regulatory compliant drug products."
GBI's new three format automated filler has capabilities to support filling in vials, syringes and cartridges, across various drug classes such as biologics, vaccines, bioconjugates and complex large molecules .
The addition of these capabilities aligns with GBI's broader mission to provide its clients with end-to-end development and cGMP manufacturing services as a Single-Source Solution™ CDMO. The company's enhanced fill-finish capacity will simplify its clients' manufacturing supply chains and help in achieving faster timelines , improved scalability, regulatory compliance and the convenience of having both DS and DP material manufactured at one site !
GBI is a leading CDMO focused on providing comprehensive, high-quality services to the global pharmaceutical and biotech sectors. With expertise in process development , analytical services , DS manufacturing and sterile fill finish for biologics, GBI supports the development and commercialization of life-saving therapies worldwide.
For more information on GBI, a drug substance and sterile fill finish CDMO visit: https://www.gbibio.com/aseptic-fill-finish/ or contact via https://www.gbibio.com/contact/ .
Media Contact: info@GbiBio.com
View original content: https://www.prnewswire.co.uk/news-releases/gbi-biomanufacturing-expands-capabilities-with-automated-aseptic-fill-finish-for-drug-products-302310878.html